Brief: Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia
BRIEF-Hutchmed (China) Says FDA Grants Orphan Drug Designation To Sovleplenib For Autoimmune Hemolytic Anemia Nov 5 (Reuters) - HUTCHMED (China) Ltd 0013.HK:
FDA GRANTS ORPHAN DRUG DESIGNATION TO SOVLEPLENIB FOR AUTOIMMUNE HEMOLYTIC ANEMIA
Further company coverage: 0013.HK
((Reuters.Briefs@thomsonreuters.com;))